当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Thomas B. Cueni, Thomas B. Cueni
Since the world’s response to COVID-19 began, we have all worked to outrun a virus that has so far proven faster than we have been. Industry, governments, hospitals, providers, suppliers, researchers indeed entire countries found themselves on their heels for much of 2020. The significant efforts and associated learnings accumulated since early 2020 enable meaningful early insights to inform the current crisis and the future course. Swift pathogen surveillance and sharing, an enabling innovation ecosystem built on strong intellectual property protections, global voluntary partnerships supporting an unprecedented manufacturing of COVID-19 vaccines and treatments, are part of the lessons learned. It is also clear however that collective efforts are needed to achieve health equity, while ensuring health systems and delivery infrastructure are strengthened. The biopharmaceutical industry, having played a critical role in the response against COVID-19, is committed to working with stakeholders and is contributing game changing solutions to equitable access to ensure vulnerable populations are prioritized.